MENU
+Compare
RPRX
Stock ticker: NASDAQ
AS OF
Aug 12, 01:55 PM (EDT)
Price
$36.07
Change
-$0.12 (-0.33%)
Capitalization
15.65B

RPRX stock forecast, quote, news & analysis

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties... Show more

RPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. RPRX showed earnings on August 06, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for RPRX with price predictions
Aug 11, 2025

Aroon Indicator for RPRX shows an upward move is likely

RPRX's Aroon Indicator triggered a bullish signal on August 11, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 202 similar instances where the Aroon Indicator showed a similar pattern. In of the 202 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RPRX advanced for three days, in of 288 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for RPRX moved out of overbought territory on August 06, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 62 cases where RPRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on August 11, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on RPRX as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for RPRX turned negative on August 11, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RPRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

RPRX broke above its upper Bollinger Band on July 28, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.465) is normal, around the industry mean (18.507). P/E Ratio (15.808) is within average values for comparable stocks, (53.654). Projected Growth (PEG Ratio) (3.149) is also within normal values, averaging (2.918). Dividend Yield (0.024) settles around the average of (0.049) among similar stocks. P/S Ratio (9.116) is also within normal values, averaging (288.769).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RPRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Dividends

RPRX is expected to pay dividends on September 10, 2025

Royalty Pharma plc RPRX Stock Dividends
A dividend of $0.22 per share will be paid with a record date of September 10, 2025, and an ex-dividend date of August 15, 2025. The last dividend of $0.22 was paid on June 10. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.79B. The market cap for tickers in the group ranges from 58 to 96.01B. VRTX holds the highest valuation in this group at 96.01B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 8%. For the same Industry, the average monthly price growth was 21%, and the average quarterly price growth was 18%. SPRBD experienced the highest price growth at 7,525%, while BIVI experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 29%. For the same stocks of the Industry, the average monthly volume growth was 99% and the average quarterly volume growth was 85%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 59
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -13 (-100 ... +100)
View a ticker or compare two or three
RPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a provider of drug development services

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
110 East 59th Street
Phone
+1 212 883-0200
Employees
89
Web
https://www.royaltypharma.com